Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning

Mary McMurray,1* Mike J Crawford,2 Joe Reilly,3,4 Juan Delport,5 Paul McCrone,6 Diane Whitham,7 Wei Tan,7 Conor Duggan,1,8 Alan A Montgomery,7 Hywel C Williams,7 Clive E Adams,1 Huajie Jin,6 Matthew Lewis5 and Florence Day7 on behalf of the PEPS Trial Collaborative Group

1Institute of Mental Health, University of Nottingham, Nottingham, UK
2Centre for Mental Health, Imperial College London, London, UK
3School of Medicine, Pharmacy & Health, Centre for Integrated Health Care Research, Durham University, Durham, UK
4Tees, Esk & Wear Valleys NHS Foundation Trust, Middlesbrough, UK
5Centre for Psychological Therapies, Cwm Taf University Health Board, Mountain Ash, UK
6Institute of Psychiatry, King’s College London, London, UK
7Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
8Partnerships in Care, Nottingham, UK

*Corresponding author

Declared competing interests of authors: Hywel Williams is Deputy Director of the National Institute for Health Research (NIHR) Programme and chairperson of the Health Technology Assessment (HTA) Commissioning Board. From 1 January 2016 he became Programme Director for the HTA programme. The NIHR HTA programme funded this study; however, Professor Williams was not involved in that funding decision.

Disclaimer: This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.

Published July 2016
DOI: 10.3310/hta20520
Scientific summary

Psychoeducation with problem-solving
Health Technology Assessment 2016; Vol. 20: No. 52
DOI: 10.3310/hta20520

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Personality disorder (PD) is one of the most prevalent forms of mental health problem, and is associated with substantial health-care and social costs. Despite this, there is relatively little reliable evidence on the effectiveness of treatments for PD.

Many treatments for PD are intensive and of long duration, which limits the amount of services that can be provided. Testing the clinical effectiveness and cost-effectiveness of shorter interventions is important if more people with PD are to be treated. Additionally, interventions that can be used with any PD have the potential for more efficient service delivery. In treating groups of people with mixed PDs, the treatment target necessarily needs to be a problem common to all. One core feature of all PDs is the experience of problems with social and interpersonal functioning. Social problem-solving therapy is one viable and empirically supported approach. Meta-analyses of problem-solving therapy outcome studies document its effectiveness for people with a wide range of mental health problems.

A combined psychoeducational intervention aimed at clarifying the PD diagnosis, identifying associated problems and leading into group problem-solving therapy has been developed. Psychoeducation with problem-solving (PEPS) therapy was evaluated with adults with PD in the community, in an exploratory trial. In this trial, those treated with PEPS therapy showed better social functioning, as measured by the Social Functioning Questionnaire (SFQ), at the end of treatment than those in a wait-list control group. Here, we present the results of a multisite randomised controlled trial of PEPS therapy.

Objectives

The study aimed to determine if PEPS therapy in addition to usual treatment compared with usual treatment alone for people with PD resulted in improved social functioning at follow-up 72 weeks after randomisation.

In addition, we planned to:

- assess the costs and cost-effectiveness of PEPS therapy compared with usual treatment alone
- examine the effects on scheduled and unscheduled use of services
- examine the effect on mood
- evaluate participants’ perceived effects of the intervention
- evaluate referrers’ perceived effects of the intervention
- examine the process of change by testing the hypotheses:
  - that psychoeducation improves the therapeutic relationship
  - that social problem-solving therapy improves social problem-solving abilities
- conduct a qualitative investigation of the receipt of PEPS in practice to identify the views of service users.
Methods

Setting
Community mental health services in three NHS trusts in England and Wales.

Participants
Eligible participants were aged $\geq 18$ years, living in the community and proficient in spoken English and had capacity to provide informed consent. At the point of randomisation, participants were required to have one or more probable PDs identified through the International Personality Disorder Examination completed at screening. Exclusion criteria were a primary diagnosis of major functional psychosis, insufficient degree of literacy, comprehension or attention to be able to engage in trial therapy and assessments, engagement in a specific programme of psychological treatment for PD or likely to start such treatment during the trial period, and participation in any other trial.

Interventions
This was a two-arm trial comparing PEPS therapy in addition to usual treatment with usual treatment only. PEPS therapy is a combination of individual psychoeducation followed by group problem-solving therapy. Psychoeducation consists of up to four sessions of information and dialogue about PDs, as experienced by the individual and as assessed by the clinician. The aims are to build rapport, improve knowledge and motivate participants for problem-solving therapy. Problem-solving therapy is a 12-session group intervention designed to help people learn a strategy for solving interpersonal problems. Usual treatment was not specified.

Training
The PEPS intervention was specified in treatment manuals, containing information about the theory underpinning the treatment, the content of sessions, and the duration and frequency of sessions. Therapists were qualified mental health nurses or psychology graduates with clinical experience. Therapists were centrally trained by experienced clinicians, and regular supervision was provided. Audiotapes of treatment delivery were scrutinised by the trainers to ensure that each therapist was adhering to the treatment specification. Competence checklists were constructed for this assessment. Cut-off scores for competence were agreed in advance and therapists were assessed for competence in delivering the treatment. None of the therapists failed to meet the competence criteria on any of the measures.

Randomisation
Randomisation was based on a computer-generated pseudo-random code using random permuted blocks of randomly varying size, created by the Nottingham Clinical Trials Unit in accordance with their standard operating procedure and held on a secure server. Allocation was stratified by recruiting centre and sex.

Blinding
Participants, mental health workers delivering the interventions and participants’ usual-care teams were aware of the treatment allocation. Most of the outcome data were obtained from self-report questionnaires from patients who were not blind to treatment allocation. However, outcome measures were administered by research assistants blinded to treatment allocation, and data entry and analyses were conducted blind to allocation.

Outcomes
- The primary outcome of social functioning was measured by the SFQ, an eight-item self-report questionnaire with scores ranging from 0 to 24. A lower score is more desirable.
- Costs and cost-effectiveness were based on the Client Service Receipt Inventory and the European Quality of Life-5 Dimensions (EQ-5D) questionnaire, a health status measure used to generate quality-adjusted life-years (QALYs).
• Scheduled and unscheduled use of services was based on information in general practitioner records,
with emergency department visits and attendances at crisis resolution teams designated unscheduled.
• Mood was measured by the Hospital Anxiety and Depression Scale (HADS), a 14-item self-report
quadrantnaire with scores ranging from 0 to 42. Higher scores are less desirable.
• Referrers’ perceived effects of the intervention were assessed using the Global Assessment of
Functioning (GAF), a rating scale used to rate the social, occupational and psychological functioning of
adults from low (score 1) to superior (score 100).
• Participants were asked to specify three main problems they wished to change and rate these on
severity on a scale from not at all distressing (0) to very distressing (10).
• Therapeutic relationship was assessed using the Working Alliance Inventory – Short Revised (WAI-SR), a
12-item scale rated by both client and therapist to assess agreement on the tasks and goals of therapy,
and the bond between client and therapist, with a range of scores between 12 (poor) and 48 (good).
• Social problem-solving abilities were measured by the Social Problem-Solving Inventory – Revised: Short
Version (SPSI-R), a 25-item self-report questionnaire that measures problem-solving orientations and
styles. A total social problem-solving score ranges from 0 to 25, with a higher score being more desirable.

Sample size

Allowing for 30% attrition, we estimated that 340 participants would be needed to detect a 2-point
difference (standardised effect size of 0.44) on the SFQ with 80% power and 1% two-sided alpha.

Analysis plan

Clinical effectiveness

The primary between-group comparison for the primary outcome was implemented using a multivariable
linear regression model following the intention-to-treat principle with multiple imputation of the missing
data. The analysis was adjusted by outcome at baseline and stratification variables and allowed for
potential clustering by problem-solving group in the PEPS arm. Sensitivity analyses were conducted as
follows: (1) intention to treat without imputation of missing data; (2) further adjustment of baseline
variables with marked imbalance between arms; and (3) estimating the impact of adherence to
intervention on treatment effect.

Analysis of secondary outcomes, health-service use and adverse events was conducted using a similar
approach as for the primary outcome, dependent on the outcome type and without imputation of missing
data. The exception to this was the SPSI-R total score, which was analysed using repeated measures by
including both SPSI-R score at 24 and 72 weeks.

Cost-effectiveness

The cost of the PEPS intervention was estimated using information on the core resources required to
deliver the individual and group sessions, and estimating specific costs for those inputs. Health service use
was measured using the Client Service Receipt Inventory. Cost data are frequently skewed; therefore,
bootstrapped estimates were planned so that mean costs could be compared while imposing no prior
assumptions regarding the data distribution. The EQ-5D was used to measure health-related quality of life,
with utility scores attached to each health state used to generate QALY gains over the follow-up period
(using area under the curve methods and assuming a linear change between any two adjacent time
points). Baseline data were analysed using a regression model to identify variables significantly associated
with cost. If PEPS resulted in higher costs and better outcomes, then incremental cost-effectiveness ratios
were to be computed. Uncertainty around these was explored using cost-effectiveness planes. In addition,
cost-effectiveness acceptability curves were generated using the net benefit approach in order to
determine the likelihood that the intervention was the most cost-effective option. These probabilities were
subsequently used to generate the cost-effectiveness acceptability curves.
Results

A difference in the number of reported adverse events caused concern about the safety of PEPS therapy and led to an early cessation of recruitment after 306 people had been randomised: 154 in the PEPS arm and 152 in the usual-treatment arm.

Follow-up at 72 weeks after randomisation was completed for 62% and 73% in the usual-treatment and PEPS arms, respectively. In addition to a greater proportion of completers, duration of follow-up among non-completers was also greater in the PEPS arm, which resulted in a total of 178 and 203 person-years of follow-up in the usual-treatment and PEPS arms, respectively.

Median attendance at the individual psychoeducation sessions was approximately 90% and for problem-solving group sessions was around 50%. Regarding group sessions, 47% ($n = 63$) received a partial intervention (i.e. $\leq 5$ group sessions) and 53% ($n = 70$) received the intervention as per protocol (i.e. $\geq 6$ group sessions). Complier average causal effect (CACE) analysis suggests that compliance increases the effect, but none of the sensitivity analyses supports different conclusions from the primary analysis.

Psychoeducation with problem-solving therapy plus usual treatment was no more effective than usual treatment alone on the primary outcome [adjusted difference in means for SFQ –0.73 points, 95% confidence interval (CI) –1.83 to 0.38 points; $p = 0.19$]. No difference was found in scheduled service use (adjusted incidence rate ratio 0.91, 95% CI 0.69 to 1.21; $p = 0.54$), unscheduled service use (adjusted incidence rate ratio 0.87, 95% CI 0.60 to 1.26; $p = 0.47$), HADS score (adjusted difference in means –1.2, 95% CI –4.2 to 1.8; $p = 0.44$) or on severity ratings of three main problems (adjusted difference in means –0.3, 95% CI –1.0 to 0.5; $p = 0.48$). Insufficient data precluded analyses of the GAF. There was no difference in the total SPSI-R score (adjusted difference in means 0.14, 95% CI –0.53 to 0.82; $p = 0.68$) or on any of the subscales. Insufficient data precluded analyses of the WAI. By the final follow-up, the mean costs for the usual-treatment group were £182 higher than for the PEPS group, but the difference was not significant. Similarly, the PEPS group had higher QALYs (adjusted difference in mean gains from baseline to end point 0.015), but the difference was not significant.

By the end of the trial, both the number of reported adverse events, including serious adverse events, and the number of people experiencing them were greater in the PEPS arm. Statistical analysis that allows for the higher follow-up in the PEPS arm shows a tendency for PEPS participants to experience more adverse events, although the results are inconclusive (adjusted incidence rate ratio 1.24, 95% CI 0.93 to 1.64).

Discussion

We found no evidence to support the use of PEPS therapy alongside standard care for improving the social functioning of adults with PD living in the community. This differs from the pilot study, in which significant improvement was found in the primary outcome of social functioning, measured, as in this trial, by the SFQ. The trial reported here was superior in its design and methods: it was multisite, there was a larger number of participants providing greater precision of estimated between-group differences, the follow-up period was considerably longer and the methods of imputing missing data were more sophisticated. Hence, greater confidence can be placed in these results. More adverse events, mainly incidents of self-harm, occurred in the PEPS arm but the difference was not significant. There may have been bias in recording adverse events because more people in the PEPS arm were followed up and for longer.
Recently, evidence has been accruing from trials that structured clinical management achieves equally good outcomes as specific treatments for PD. It may be that specialist treatments benefited primarily by minimising harm, possibly through preventing unco-ordinated care. In the PEPS trial, treatment was delivered as a stand-alone therapy rather than being integrated into a co-ordinated package of care. This may have been a serious shortcoming. One possible explanation for the higher number of reported adverse events in the treatment arm is that the treatment stopped without any structured follow-up, thus leaving participants unsupported after a period of treatment. To have one’s support withdrawn may be more damaging than to have had little or no support in the first place.

**Conclusion**

Psychoeducation with problem-solving therapy should not be promoted for people in mental health services who are diagnosed with PD, at least not in the absence of a structured, comprehensive clinical care package. Harm is most likely to be caused by leaving people unsupported after the conclusion of brief interventions rather than by PEPS itself, with some evidence for this being the CACE analysis showing that more uptake of treatment leads to better outcomes. Use of any brief problem-solving interventions in practice should be conducted only with rigorous collection of data on adverse effects, in the context of the need for better awareness and measurement of adverse events in psychotherapy practice as a whole.

Overall, participants in this trial were heavy users of health services, costing approximately £8000 per annum (based on baseline data). This is reflected in low quality of life, with QALYs of approximately 0.57 over the entire follow-up (out of a possible 1.5 QALYs). It is important to continue to seek effective management and treatment for this group of individuals.

**Trial registration**

The trial is registered as ISRCTN70660936.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Health Technology Assessment

Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report
The research reported in this issue of the journal was funded by the HTA programme as project number 08/53/06. The contractual start date was in February 2010. The draft report began editorial review in November 2014 and was accepted for publication in December 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk